B. Thürlimann

450 total citations
15 papers, 150 citations indexed

About

B. Thürlimann is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, B. Thürlimann has authored 15 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in B. Thürlimann's work include Estrogen and related hormone effects (6 papers), Breast Cancer Treatment Studies (5 papers) and Bone health and treatments (4 papers). B. Thürlimann is often cited by papers focused on Estrogen and related hormone effects (6 papers), Breast Cancer Treatment Studies (5 papers) and Bone health and treatments (4 papers). B. Thürlimann collaborates with scholars based in Switzerland, United Kingdom and United States. B. Thürlimann's co-authors include Hervé Bonnefoi, R. Morant, F. Cavalli, M. Castiglione, Martin F. Fey, AS Coates, A. Goldhirsch, JF Forbes, Monica Castiglione‐Gertsch and Z. Herrmann and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

B. Thürlimann

13 papers receiving 136 citations

Peers

B. Thürlimann

ONCOL

GENET

PRM

OSM

Catherine Elliott United States

Kathi Malone United States

Riccardo Rosso Italy

Irene E.G. van Hellemond Netherlands

Polly A. Newcomb United States

V. Labonia Italy

Krystyna Reczko United Kingdom

Myoungkeun Lee United States

John L. Hopper Australia

Maria do Socorro Maciel Brazil

Catherine Elliott United States

B. Thürlimann

80 ×0.7

ONCOL

49 ×0.9

GENET

45 ×1.0

33 ×1.0

PRM

21 ×1.1

OSM

Citations per year, relative to B. Thürlimann B. Thürlimann (= 1×) peers Catherine Elliott

Countries citing papers authored by B. Thürlimann

Since Specialization

Citations

This map shows the geographic impact of B. Thürlimann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Thürlimann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Thürlimann more than expected).

Fields of papers citing papers by B. Thürlimann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Thürlimann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Thürlimann. The network helps show where B. Thürlimann may publish in the future.

Co-authorship network of co-authors of B. Thürlimann

This figure shows the co-authorship network connecting the top 25 collaborators of B. Thürlimann. A scholar is included among the top collaborators of B. Thürlimann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Thürlimann. B. Thürlimann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Šestak, Ivana, MM Regan, Andrew Dodson, et al.. (2018). Abstract GS6-01: Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy. Cancer Research. 78(4_Supplement). GS6–1. 1 indexed citations

Borgquist, Signe, Anita Giobbie‐Hurder, Thomas P. Ahern, et al.. (2016). Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study. Cancer Research. 76(4_Supplement). PD1–3. 2 indexed citations

Templeton, Arnoud J., J. Bernhard, Peter Brauchli, et al.. (2014). Prevention of Symptomatic Skeletal Events with Denosumab Administered Every 4 Weeks Versus Every 12 Weeks–A Non-Inferiority Phase III Trial: Sakk 96/12 - Reduse. Annals of Oncology. 25. iv540–iv540. 9 indexed citations

Huober, J., Jian Wu, Anita Giobbie‐Hurder, et al.. (2011). Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.. Journal of Clinical Oncology. 29(15_suppl). 522–522. 6 indexed citations

Censi, Andrea De, Zheng Sun, B. Thürlimann, et al.. (2011). Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.. Journal of Clinical Oncology. 29(15_suppl). 516–516.

Bouzyk, Mark, Kathryn P. Gray, Meredith M. Regan, et al.. (2011). ESR1 and ESR2 polymorphisms in BIG 1−98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1002–1002. 1 indexed citations

Giobbie‐Hurder, Anita, MM Regan, Patrizia Dell’Orto, et al.. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. Journal of Clinical Oncology. 26. 5569–5575. 3 indexed citations

Rizzoli, R., D. Thiébaud, Nigel Bundred, et al.. (1999). Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3545–3550. 32 indexed citations

Thürlimann, B., et al.. (1999). Papillary Thyroid Carcinoma in an Adult Teratoma in Combination with Mucinous Cystadenoma of the Ovary. Oncology Research and Treatment. 22(3). 222–224. 1 indexed citations

10.

Bernhard, Jürg, Christoph Hürny, AS Coates, et al.. (1998). Factors affecting baseline quality of life in two international adjuvant breast cancer trials. British Journal of Cancer. 78(5). 686–693. 33 indexed citations

11.

Thürlimann, B., M. Castiglione, F. Cavalli, et al.. (1997). Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). European Journal of Cancer. 33(7). 1017–1024. 51 indexed citations

12.

Thürlimann, B., et al.. (1996). [Hormone therapy of metastasizing breast carcinoma].. PubMed. 53(11). 820–8.

13.

Rizzoli, R., D. Thiébaud, N.J. Bundred, et al.. (1995). Pathophysiology of malignant hypercalcemia in relation with serum parathyroid hormone-related protein levels and response to the bisphosphonate ibandronate. Bone. 17(6). 616–616. 2 indexed citations

14.

Thürlimann, B., et al.. (1993). Improvement of Palliation in Patients with Osteolytic Bone Disease and Unsatisfactory Pain Control after Pretreatment with Disodium Pamidronate: An Intra-Patient Dose Escalation Study. Oncology Research and Treatment. 16(3). 174–177. 7 indexed citations

15.

Thürlimann, B., et al.. (1991). Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Intensification of Cytostatic Treatment in Advanced Cancer. Recent results in cancer research. 121. 173–181. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact